M. Mark Mofid – Trademark Portfolio

Entity Type: 01

M. Mark Mofid holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include SYLKE. The owner is based in La Jolla, CA.

4150 Regents Park Row, Suite 300

La Jolla, CA 92037

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SYLKE
SYLKE
Pending 2023
SYLKE MD
SYLKE MD
Abandoned 2022
SYLKE
SYLKE
Registered 2022

Trademark Classifications

M. Mark Mofid's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does M. Mark Mofid have?

M. Mark Mofid has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending, 1 abandoned.

What trademark classes does M. Mark Mofid file in?

M. Mark Mofid files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are M. Mark Mofid's most well-known trademarks?

M. Mark Mofid's registered trademark portfolio includes well-known marks such as SYLKE. These are among 1 currently registered trademark in the portfolio.

What is M. Mark Mofid's trademark registration success rate?

M. Mark Mofid has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 2 applications are pending review.